Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Haque, Nazneen | - |
dc.contributor.author | Masumori, Naoya | - |
dc.contributor.author | Sakamoto, Sadaaki | - |
dc.contributor.author | Ye, Zhangqun | - |
dc.contributor.author | Yoon, Sang-Jin | - |
dc.contributor.author | Kuo, Hann-Chorng | - |
dc.contributor.author | Brotherton, Betsy | - |
dc.contributor.author | Wilson, Timothy | - |
dc.contributor.author | Muganurmath, Chandra | - |
dc.contributor.author | McLaughlin, Megan | - |
dc.contributor.author | Manyak, Michael | - |
dc.date.available | 2020-02-27T08:42:11Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 0919-8172 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3105 | - |
dc.description.abstract | Objectives To assess the effectiveness and safety of dutasteride 0.5 mg + tamsulosin 0.2 mg combination compared with tamsulosin 0.2 mg in Asian men with moderate-to-severe benign prostatic hyperplasia. Methods A 4-week, single-blind, placebo, run-in was followed by a 2-year double-blind randomized controlled trial in men age >= 50 years with symptomatic benign prostatic hyperplasia, International Prostate Symptom Score >= 12, prostate volume >= 30 cc, prostate-specific antigen >= 1.5 and <= 10 ng/mL, peak urinary flow >5 and <= 15 mL/s, and voided volume of >= 125 mL. Participants were randomized to oral daily dutasteride 0.5 mg + tamsulosin 0.2 mg combination or tamsulosin 0.2 mg. The primary efficacy end-point was change in International Prostate Symptom Score at year 2. Results Data from 607 participants showed a significant reduction in International Prostate Symptom Score (P < 0.05) at month 24, along with greater improvements (P <= 0.006) in peak urinary flow at every assessment and significant prostate volume reduction at months 12 and 24 (P < 0.001) in the combination group. Combination therapy was associated with a significant reduction in the risk of acute urinary retention or benign prostatic hyperplasia-related surgery (P = 0.012), primarily due to a significant reduction in the risk of acute urinary retention (P = 0.005). The safety and tolerability profile of combination therapy was consistent with the known profiles for the individual monotherapies. Conclusions Dutasteride 0.5 mg + tamsulosin 0.2 mg combination therapy showed better clinical outcomes than tamsulosin 0.2 mg monotherapy, making it an effective and safe treatment option for Asian men with moderate-to-severe benign prostatic hyperplasia. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF UROLOGY | - |
dc.subject | URINARY-TRACT SYMPTOMS | - |
dc.subject | COMBINATION THERAPY | - |
dc.subject | FINASTERIDE | - |
dc.subject | PREVALENCE | - |
dc.subject | GUIDELINES | - |
dc.title | Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000449840700007 | - |
dc.identifier.doi | 10.1111/iju.13785 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF UROLOGY, v.25, no.11, pp.944 - 951 | - |
dc.identifier.scopusid | 2-s2.0-85052932247 | - |
dc.citation.endPage | 951 | - |
dc.citation.startPage | 944 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF UROLOGY | - |
dc.citation.volume | 25 | - |
dc.citation.number | 11 | - |
dc.contributor.affiliatedAuthor | Yoon, Sang-Jin | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | benign prostatic hyperplasia | - |
dc.subject.keywordAuthor | combination therapy | - |
dc.subject.keywordAuthor | dutasteride | - |
dc.subject.keywordAuthor | International Prostate Symptom Score | - |
dc.subject.keywordAuthor | tamsulosin | - |
dc.subject.keywordPlus | URINARY-TRACT SYMPTOMS | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | FINASTERIDE | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.